VIGIBASE registry RA 39000+ pts JAKi and 231000+ pts TNFi *No increase in MACEs with JAKi 1.4% vs. 0.9% *JAKi Increase in DVT RR 3.99 and PE RR 3.5 adjusted on age and sex @RheumNow #OP0268 #EULAR2022 #Lupus https://t.co/hiAvKctgky

Gilbert et al. RA assoc increased risk hospitalisation or death from COVID-19 1.53 (1.20, 1.94). RA-ILD assoc even greater risk hospitalisation or death multivariable HR 2.84 [95% CI 1.64-4.91] @RheumNow #EULAR2022 OP0251 https://t.co/h1jzAV6xNR https://t.co/7E1EzAKCDv

• EULAR Abstract Archive

Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow

#ClinicalPearl. Why do doctors prescribe #JAKi in RA? Efficacy, fast onset, X-ray inhibition, can work as monotherapy, remission - in order of diminishing frequency BUT I will add access and oral (convenience). POS0680 @RheumNow @eular_org #EULAR2022 https://t.co/XHtNqguqvh

Boers et al. GLORIA trial of long term 5mg pred in RA. Titled as "favourable balance of benefit and harm". I cannot agree. 24% increase adverse events, NNH 9, for DAS28 0.37 better at 1 year, and really no difference after that. @RheumNow #EULAR2022 OP0263 https://t.co/eO4f1CjH5q https://t.co/VyyZm1QvYy

• EULAR Abstract Archive

Deep learning can be used to distinguish seropositive RA from seronegative RA and PsA based on MRI. Early changes in PsO may suggest a PsA-like MRI pattern may be present! Is this how we predict which PsO -> PsA? @RheumNow #EULAR2022 ABST#OP0292 https://t.co/NGfFkSqlaM

#EULAR2022 POS0213 Beware of paradoxical low lipids in RA! ⭐️ETN+MTX vs MTX T2T: Early ETN: increased in HLD, lesser LDL, differs from MTX. Correlates with clinical disease activity @RheumNow https://t.co/c6GXadVwYN

#EULAR2022 POS0207 Fatigue in early RA: ⭐️Does not show direct effect between inflammation on fatigue ⭐️Suggests broader indirect effect of psychosocial aspects of wellbeing (pain, mental health, sleep, disease perception) plays larger role @Rheumnow https://t.co/zTxk7kZRIX

Szekanecz et al. ORAL Surveillance. Geographic differences in MACE largely driven by history CVD and high baseline risk in North America and ROW. @RheumNow #EULAR2022 POS0110 https://t.co/cR6a7N2KP5

The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves the serologic response follow the first two vaccine doses and allowed them to close the gap compared to the two-dose vaccinated controls #EULAR2022 @RheumNow OP0192 Jyssum et al

#EULAR2022 POS0210 RNA sequencing in 11 RA-ILD patients vs 9 RA pts ⭐️Distinct gene expression in RA-ILD with type 1 IFN response, neutrophil activation, and degranulation and CCR1 chemokine interactions @RheumNow @fahidalghanim https://t.co/FIrZfzZV1C

#EULAR2022 OP0278: Increase in risk of CVA compared to general population ~1.2x risk ⭐️This is unchanged between the pre-biologic (1972-1998) and the post-biologic treatment era ⭐️Interesting finding: smoking rate same over time in RA, despite decr in Norway in gen pop @Rheumnow https://t.co/r8QsJABfvx

Charles-Schoeman et al. ORAL Surveillance. PE risk factors - History VTE, antidepressant use, obesity, steroids, male, age, OCP/HRT. PPI protective @RheumNow #EULAR2022 POS0239 https://t.co/fDLKrpvpgI

Can we predict VTEs from JAKi for RA at all? Baseline elevated D-dimer pts who go on to develop VTE (but not baseline CRP, so not just general inflamm) Questions raised about effect modification for VTE following JAKi too. This story not yet done OP0269 #EULAR2022 @RheumNow https://t.co/ErDcFpXXUl